1. health and fitness
2. therapy

New drugs and new regimens for the treatment of tuberculosis:
review of the drug development pipeline and implications for
national programmes
Christian Lienhardta, Andrew Vernonb and Mario C. Raviglionec
a
Stop TB Department and Stop TB Partnership, World
Health Organization, Geneva, Switzerland, bClinical and
Health Systems Research Branch, Division of TB
Elimination, U.S. Centers for Disease Control and
Prevention, Atlanta Georgia, USA and cStop TB
Department, World Health Organization, Geneva,
Switzerland
Correspondence to Christian Lienhardt, MD, MSc, PhD,
Stop TB Department and Stop TB Partnership, World
Health Organization, Geneva, Switzerland
Tel: +41 22 791 25 86; fax: +41 22 791 48 86;
e-mail: lienhardtc@who.int
Current Opinion in Pulmonary Medicine 2010,
16:186–193
Purpose of review
The aim is to review briefly the problems related to treatment of drug-susceptible and
drug-resistant tuberculosis (TB), describe recent advances in the development of new
drugs and new regimens, and discuss implications for control programmes.
Recent findings
Encouraging advances in TB drug research and development have been made since the
turn of the century, resulting in a large number of new products introduced into the
global portfolio.
Summary
Currently, nine compounds at least have advanced to clinical development, including
four existing drugs redeveloped for TB indication and five new chemical entities. Present
clinical trials are testing new combinations of drugs for a shortened treatment of drugsusceptible TB (<6 months duration) or the safety and efficacy of new drugs in addition
to an optimized background therapy for the treatment of multidrug-resistant TB. There
are at least 34 compounds or projects in the discovery and preclinical stages, including
eight compounds in preclinical development. This increasing development of single
compounds underscores the needs for a novel approach to test for optimal drug
combinations that would be proposed for treatment of TB in all its forms, and the
necessary collaboration of pharmaceutical companies, academia, research institutions,
donors, and regulatory authorities.
Keywords
drug development, drug-resistant tuberculosis, drug-susceptible tuberculosis,
multidrug therapy
Curr Opin Pulm Med 16:186–193
ß 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
1070-5287
Introduction
Current treatment of tuberculosis (TB) is based on drugs
that are more than 40 years old. Despite a demonstrated
high efficacy in clinical trials [1], standardized short-course
chemotherapy (SCC) of active drug-susceptible TB
requires direct supervision to assure good adherence and
prevent drug resistance [2]. Drugs that are active against
resistant forms of TB are less potent, more toxic, and need
to be taken for a long time (18 months). The recent
emergence of virtually untreatable extensively drug-resistant TB (XDR-TB) poses a new threat to TB control
worldwide. Furthermore, effective treatment of TB in
persons coinfected with HIV is complicated due to
drug–drug interactions. Shorter and simpler regimens that
are safe, well tolerated, effective against drug-susceptible
and drug-resistant TB, appropriate for joint HIV–TB
treatment, and amenable to routine programmatic conditions are needed urgently. In the present paper, we
review the problems related to current treatment of TB
1070-5287 ß 2010 Wolters Kluwer Health | Lippincott Williams & Wilkins
and its variants, and discuss recent advances in the development of new drugs and new regimens for the treatment
of drug-susceptible and drug-resistant TB.
The current treatment of tuberculosis
The current treatment of drug-susceptible TB is the
result of a comprehensive series of trials conducted over
20 years by the British Medical Research Council [1] that
has led to the definition of a 6-month four-drug regimen.
Treatment of drug-susceptible tuberculosis in newly
detected patients
The 6-month regimen includes rifampin, isoniazid,
pyrazinamide, and ethambutol given daily or intermittently for two months, followed by rifampin and isoniazid
for four months (Table 1). Treatment-limiting side effects
vary [3], but most are not severe. Treatment regimens that
are intermittent, or use rifampin during the intensive phase
of treatment, offer some practical advantages, but their
DOI:10.1097/MCP.0b013e328337580c
New drugs–regimens for the treatment of TB Lienhardt et al.
187
Table 1 Antituberculosis agents for treatment of drug-susceptible and drug-resistant tuberculosis
Group
Drugs
Characteristics
Group 1
First-line oral agents – isoniazid,
rifampicin, ethambutol, and pyrazinamide
The most potent and best tolerated agents to be used in
combined 6-month chemotherapy – each should be used
if there is laboratory evidence and clinical history to
suggest that it is effective. For patients with strains
resistant to low concentrations of isoniazid but
susceptible to higher concentrations, the use of
high-dose isoniazid may have some benefit (when
isoniazid is used in this manner, it is considered a
Group 5 drug; see below).
Rifabutin is used in place of rifampin under
certain conditions such as treatment of
TB in HIV patients on protease inhibitors.
Rifapentine, a long-acting rifamycin,
recommended by CDC for once-weekly
continuation phase in low-risk, HIV-negative
TB patients is presently in trials for treatment
shortening, using higher or daily dosing.
These two newer generation rifamycins have
high cross-resistance to rifampin.
All patients with MDR-TB should receive a Group 2
injectable agent if susceptibility is documented or
suspected. Use of kanamycin or amikacin should be
preferred, given the high rates of streptomycin
resistance in drug-resistant TB patients and the fact
that both these agents are low cost, have less toxicity
than streptomycin, and have been used extensively for
the treatment of drug-resistant TB throughout the world.
All patients with MDR-TB should receive a Group
3 medication if the strain is susceptible or if the agent is
thought to have efficacy. Currently, the most potent
available fluoroquinolones in descending order based
on in-vitro activity and animal studies are:
moxifloxacin ¼ gatifloxacin > levofloxacin > ofloxacin.
If gatifloxacin is used, patients should undergo close
monitoring and follow-up due to reports of severe
dysglycaemia.
Group 4 medications are added based on estimated
susceptibility, drug history, efficacy, side-effect
profile, and cost.
Group 5 drugs are not recommended by WHO for routine
use in drug-resistant TB treatment because their
contribution to the efficacy of multidrug regimens is
unclear. Although they have demonstrated some
activity in vitro or in animal models, there is little or no
evidence of their efficacy in humans for the treatment
of drug-resistant TB. However, they can be used in
patients in whom adequate regimens are impossible to
design with the medicines from Groups 1 to 4 in
consultation with an expert in the treatment of
drug-resistant TB.
New generation rifamycins –
rifabutin and rifapentine
Group 2
Injectable agents – kanamycin, amikacin,
capreomycin, and streptomycin
Group 3
Fluoroquinolones – moxifloxacin,
gatifloxacin, levofloxacin, and ofloxacin
Group 4
Oral bacteriostatic second-line agents – thioamides
(ethionamide and prothionamide), cycloserine,
terizidone, and p-aminosalicylic acid
Agents with unclear efficacy (not recommended by
WHO for routine use in MDR-TB patients) –
clofazimine, linezolid, amoxicillin/clavulanate,
thioacetazone, imipenem/cilastatin, high-dose
isoniazida, and clarithromycin
Group 5
CDC, Centers for Disease Control; MDR, multidrug resistant; TB, tuberculosis.
a
High-dose isoniazid is defined as 16–20 mg/kg per day.
efficacy has been challenged in comparison with the
6-month regimen, including rifampin throughout [4]. In
a systematic review of regimens in previously untreated
patients with bacteriologically confirmed pulmonary TB,
regimens utilizing rifampin for the first 2 months only had
significantly higher rates of failure, relapse, and acquired
drug resistance than regimens that used rifampin for
6 months [5]. There was little difference in efficacy
between daily or thrice-weekly schedules of treatment,
but there was insufficient evidence to support administration of twice-weekly treatment throughout therapy. As
a result, the WHO now recommends the universal use of
the 6-month rifampin throughout SCC regimen for the
treatment of drug-susceptible TB, given under strict
supervision [6].
Treatment of tuberculosis in patients previously treated,
with monoresistance to isoniazid, or both
A single 8-month ‘retreatment’ regimen (including isoniazid, rifampin, and ethambutol, with pyrazinamide
added for the first 3 months and streptomycin added
for the first 2 months – 2SHRZE/1HRZE/5HRE) was
earlier recommended for patients with a history of prior
treatment of TB [7] and is still commonly used worldwide
188 Infectious diseases
[8]. This regimen was initially designed for resource-poor
settings with low prevalence of initial drug resistance,
and for patients previously treated with a regimen that
included rifampin administered only for the first 2 months
of therapy. This regimen was considered adequate
for patients with resistance to a single drug other than
rifampin (e.g. isoniazid). However, it has been criticized
[9] because of poor results in settings of high initial drug
resistance [8,10] or when rifampin is used throughout the
initial phase [11]. Importantly, no randomized trial of
the 8-month retreatment regimen has ever been conducted [12]. A meta-analysis [12] of studies of rifampin-containing regimens in patients with monoresistance
to isoniazid showed that longer duration of rifampin, use
of streptomycin, daily therapy initially, and treatment
with a greater number of effective drugs were associated
with lower rates of failure, relapse, and acquired drug
resistance. This reinforces the need to expand access to
drug sensitivity testing (DST) and to develop an evidence base for treatment recommendations in previously
treated patients (of note, the standard 8-month ‘retreatment’ regimen may still be used in patients who relapse
or return after default but not in those who fail treatment
[7]).
in combining these drugs derive from (i) potentially
severe drug–drug interactions between rifampin and
selected ART drugs (particularly the protease inhibitors)
and (ii) the emergence of the immune reconstitution
inflammatory syndrome (IRIS) characterized by a worsening clinical picture or the appearance of new TB
lesions [19,22,23]. Drug interactions arise because rifampin is a potent inducer of the hepatic cytochrome CYP450
enzyme system that reduces the plasma concentration of
coadministered drugs metabolized through this pathway.
Recent studies [24,25] suggest, however, that efavirenzbased regimens are compatible with rifampin-based TB
therapy, whereas standard twice-daily doses of nevirapine
may provide acceptable (though slightly inferior) efficacy
and safety in patients with contraindications to efavirenz.
The situation is more complex for coinfected patients
treated with ART regimens containing protease inhibitors, as their concentrations are decreased by concomitant use of rifampin [26]. Because of its lower effect on
protease inhibitor concentrations, rifabutin has been proposed as an alternative to rifampin, and studies are
currently underway to define a safe and effective standardized dosing approach when combined with protease
inhibitors [27,28].
Treatment of multidrug-resistant tuberculosis and
extensively drug-resistant tuberculosis
Treatment of latent tuberculosis infection
Combinations of first and second-line drugs are used for
the treatment of multidrug-resistant TB (MDR-TB) and
XDR-TB based on the results of DST [13] (Table 1).
Current regimens for MDR-TB and XDR-TB are, however, complicated due to long duration, high toxicity,
poor tolerance, and high cost, resulting in poor outcomes
[8,14]. In a recent meta-analysis [15] of 33 studies, the
overall treatment success rate (proportion of patients who
were cured or completed treatment) was only 62% [95%
confidence interval (CI) 58–67], with a nonstatistically
significant 10% difference in treatment success between
studies of individualized (64%, 95% CI 59–68) and standardized treatment regimens (54%, 95% CI 43–68). In
another meta-analysis [16] of 36 studies, 62% (95% CI 57–
67) of patients had successful outcomes, whereas 13%
(95% CI 9–11) defaulted, 11% (95% CI 9–13) died, and
2% (95% CI 1–4) were transferred out. Reported mortality
among patients with HIV infection is particularly high
[14,17]. Simpler, safer, and more effective treatments for
MDR-TB are, therefore, an urgent priority [18].
Treatment of tuberculosis–HIV coinfection
Early introduction of antiretroviral therapy (ART) has
been shown to reduce the incidence of HIV-associated
TB [19]. Although the optimal time to start ART in HIVinfected TB patients has not yet been defined [20],
most recent WHO guidelines recommend starting
ART as soon as possible after diagnosis of TB, regardless
of CD4 lymphocyte count [21]. The two main difficulties
The objective of latent tuberculosis infection (LTBI)
treatment is to prevent the development of TB disease in
high-risk populations such as contacts of infectious
patients or TB-infected HIV-positive patients. Isoniazid
monotherapy reduces the risk of TB in contacts of
infectious TB patients by at least 60% over 2 years when
taken for 6–9 months [29–31]. A 4-month daily rifampin
regimen may result in better compliance and fewer
adverse events than combined rifampin regimens or
the 6–9-month isoniazid regimen [32–34,35]. In HIVpositive individuals, isoniazid monotherapy has been
shown to reduce the risk of TB by about 60% (95% CI
51–81), with a greater benefit among tuberculin skin testpositive individuals (62%) than among people with a
negative test (17%) [36]. In this population, however,
diagnosis of LTBI and exclusion of active TB are difficult, especially in resource-poor, high-prevalence settings
[37].
Recent advances in clinical development
After 40 years of neglect, encouraging advances have
been made in TB drug research and development, resulting in a large number of new projects introduced into the
global portfolio. Currently, there are at least nine compounds in clinical development: two in phase III, four in
phase II, and three in phase I trials (Stop TB Partnership
Working Group on New TB Drugs 2009) (Table 2).
Among these, four are existing drugs redeveloped for a
TB indication and five are new chemical entities (Fig. 1).
New drugs–regimens for the treatment of TB Lienhardt et al.
189
Table 2 The clinical development phases
Phase I trials
Phase II trials
Phase III trials
Phase IV trials
Initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated
with increasing doses, and to gain early evidence of effectiveness; may include healthy participants or patients.
Controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in
patients with the disease or condition under study and to determine the common short-term side effects and risks. This
phase can also be used to establish dose ranges and dose–response relationships. Phase IIa addresses dose and
dose–response with limited numbers of participants (typically 30–50), whereas phase IIb engages risks and efficacy
with larger numbers of participants (typically 200–500).
Expanded controlled and uncontrolled trials conducted after preliminary evidence suggesting effectiveness of the drug
has been obtained, that are intended to gather additional information to evaluate the overall benefit–risk relationship
of the drug and provide adequate basis for physician labeling based on established short and long-term safety and
efficacy of the drug.
Postmarketing studies to delineate additional information, including the drug’s risks, benefits, and optimal use
in populations.
Source: http://clinicaltrials.gov/ct2/info/ from ClinicalTrials.gov 2009.
Clinical (re-)development of existing drugs
A number of known drugs are being currently investigated for their contribution in simplification or improvement of the current TB drug regimen. These include
rifamycins and fluoroquinolones.
Rifamycins (rifampin and rifapentine)
Rifampin, used at 10 mg/kg, is the cornerstone of first-line
therapy against TB. Higher doses have recently been
shown to have higher bactericidal activity [38], and
clinical trials assessing the potential use of high-dose
rifampin to shorten TB treatment will begin soon.
Because of its greater potency against Mycobacterium
tuberculosis and its longer half-life compared with rifampin, rifapentine is an attractive candidate for shortening
or simplifying therapy [39]. In an earlier phase III trial
using a once-weekly rifapentine and isoniazid in the
continuation phase of treatment, efficacy was suboptimal,
especially in HIV-infected patients who were at
increased risk of relapse with acquired rifamycin resistance [40,41]. Recent studies [42,43] in the mouse model
suggested that a regimen of daily rifapentine, pyrazinamide, and either isoniazid or moxifloxacin could
dramatically shorten the duration of treatment. Phase
II trials are underway to evaluate the ability of rifapentine
given 5 or 7 days a week to shorten the treatment.
Fluoroquinolones
Fluoroquinolones are broad-spectrum antimicrobial agents
that have shown potent activity against M. tuberculosis
in vitro and in vivo. They are used as second-line drugs in
MDR-TB treatment [44,45]. Two newer methoxyfluoroquinolones, gatifloxacin and moxifloxacin, have demonstrated more potent in-vitro activity against M. tuberculosis
than the older compounds, ofloxacin and ciprofloxacin
[46–49]. In a phase II trial in South Africa, the rates of
Figure 1 Compounds that are currently in preclinical or clinical development for the treatment of active tuberculosis
Produced by the Working Group on New Drugs of the Stop TB Partnership.
190 Infectious diseases
elimination of M. tuberculosis from serial sputum cultures
collected over the first 2 months of treatment were more
rapid when gatifloxacin or moxifloxacin, but not ofloxacin, were substituted for ethambutol in the intensive
phase of therapy [50]. Three other phase IIb trials
investigated the effect of moxifloxacin, substituted
either for ethambutol or isoniazid during the intensive
phase of treatment, on culture conversion at 2 months;
one found a dramatic effect on 2-month sputum conversion [51], whereas the other two showed limited or no
effect [52,53]. Both compounds are presently in phase
III trials evaluating their potential for shortening therapy
of drug-susceptible TB when substituted for ethambutol
or isoniazid in a 4-month regimen [54].
New drugs in clinical development
Much progress has been done in drug development over
the past decade. Here, we present the compounds that
are presently in clinical development phases.
Diarylquinolines (TMC-207)
TMC-207, a novel ATP synthase inhibitor developed by
Tibotec BVBA, Mechelen, Belgium, is highly potent
against both drug-susceptible and drug-resistant strains
of M. tuberculosis [55]. In a 7-day early bactericidal
activity (EBA) study [56], TMC-207 at a dose of
400 mg daily demonstrated late (5–7 days) bactericidal
activity similar to that of isoniazid or rifampin. The safety
and efficacy of TMC-207 is being evaluated in a phase
IIb placebo-controlled, double-blind, randomized trial
in newly diagnosed MDR-TB patients, in which either
the investigational drug or placebo is added to an
optimized background regimen. Results in the initial
group of 50 patients showed that the TMC-207 arm
achieved a significantly higher rate of sputum culture
conversion at 2 months (48% in the TMC arm vs. 9% in
the placebo arm) [57]. The second stage of the study is
now evaluating microbiological outcomes at 6 months in
200 patients.
Nitroimidazoles (PA-824 and OPC-67683)
Nitroimidazoles belong to a novel class of antimycobacterial agents that are active against drug-susceptible and
drug-resistant organisms [58]. They show similar activity
against both replicating and nonreplicating organisms,
which suggests a potential to shorten the therapy [59].
Two nitroimidazoles are currently in clinical development. The first, OPC-67683, developed by Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan), is a member of the
nitroimidazo-oxazole subclass [60]; it is currently being
evaluated in a phase II trial for the treatment of MDRTB. The second, PA-824, a member of the nitroimidazooxazine subclass, is being developed by the TB Alliance
New York City, New York, USA, and has shown good
safety and tolerability in adult pulmonary TB patients in
South Africa when given once daily for 7 days [61].
Oxazolidinones (linezolid and PNU-100480)
As a class, oxazolidinones possess a broad spectrum of
antibiotic activity, encompassing anaerobic and Grampositive aerobic bacteria, as well as mycobacteria [62].
Linezolid, the only approved drug in the class, has
modest in-vitro activity against M. tuberculosis. Although
used off-label in combination regimens for the treatment
of MDR-TB, its efficacy is unclear. Modest EBA against
M. tuberculosis was reported in patients with cavitary
pulmonary TB during the first 2 days of administration,
but the effect waned thereafter [63]. A retrospective
assessment in four European countries did not show
objective advantages of adding linezolid 600 mg daily
to individualized multidrug regimen for treatment of
MDR-TB/XDR-TB patients due to severe side effects
[64]. A retrospective review [65] in the United States,
however, reported more positive findings. A reduced
dose of 300 mg might retain efficacy while causing fewer
side effects [66]. Linezolid 600 mg is presently being
tested in a phase IIa trial for treatment of XDR-TB in the
Republic of Korea, and the 300 mg dose is under investigation in a phase IIa MDR-TB pilot trial in South
Africa.
PNU-100480 is a close analogue of linezolid developed
by Pfizer, New York City, New York, USA, that demonstrated slightly better activity in vitro [67]. Recent mouse
model studies [68,69] showed marked improvement of
bactericidal activity when added to current first-line TB
drugs or used in combination with moxifloxacin and
pyrazinamide. These findings suggest that PNU100480 has the potential to significantly shorten therapy
for both drug-susceptible and drug-resistant TB. This
compound is currently in phase I trials.
Ethylenediamines (SQ-109)
SQ-109 is a derivative of ethambutol that appears to have
a different mechanism of action [70]. The substitution of
SQ-109 for ethambutol in the standard regimen demonstrated increased efficacy in the mouse model [71]. A
phase I single-dose study has been completed and a
phase I dose-escalation study is underway.
New drugs in preclinical development
Development of new drugs is a complex, lengthy, and
expensive process, involving a series of stages (discovery,
lead identification, and lead optimization), ultimately
leading into preclinical development [72]. Each of
these early stages has a substantial rate of attrition. There
are today at least 34 compounds or projects in the
discovery and preclinical stages, including eight compounds in preclinical development, seven projects in
lead optimization, six in lead identification, and 14
in the high-throughput screening stage of discovery
(Fig. 1).
New drugs–regimens for the treatment of TB Lienhardt et al.
The programmatic implications
A unique series of critical challenges must be faced in the
development of new drugs for TB. First, as the 6-month
standard regimen has 95% efficacy under trial conditions,
the most appropriate design to test the efficacy of new
drugs/regimens for drug-susceptible TB is one of noninferiority. This requires the recruitment of a large number of patients who must be followed closely for a long
period of time (usually 12–24 months after treatment)
in order to detect trial endpoints (failure and relapse)
reliably [73]; such trials are thus lengthy and expensive,
typically costing tens of millions of dollars. A second
challenge is the need for combination therapy in order
to inhibit the growth of various mycobacterial populations
and prevent the development of drug resistance. If, for
selection of a proper combination, new drugs were added
to, or substituted into, the current regimen one at a time,
it would take 20–30 years to develop a new regimen that
contains three to four new drugs [54]. This has led drug
developers to select the use of superiority trial designs in
MDR-TB patients, that entail testing the new drug
against placebo, in conjunction with an optimized background therapy determined according to patients’ treatment experience and DST results [74]. This approach
requires much smaller sample sizes than noninferiority
trials, and allows an equal distribution of key potential
confounding factors between study arms. This, however,
may have labelling implications, as if a drug receives
provisional licensing as an addition to an optimized regimen for MDR-TB, its role in the treatment of drugsusceptible TB and the selection of appropriate companion drugs remain to be established. Furthermore, given
that misuse of a new compound may induce rapid emergence of drug resistance, a programmatically essential
question arises concerning the strategy for introduction of
a new compound into the public and private sectors. This
issue should be addressed early in the process of drug
development, ideally before new drugs are marketed.
This highlights the difficulty of translating the initial
regulatory approval of a new drug into subsequent recommendations for combination treatment regimens. It also
underscores the need for an innovative approach to
identify optimal new drug combinations that would
involve pharmaceutical companies, academia, research
institutions, donors, and regulatory authorities.
191
with nine compounds already in the clinical development
pipeline, including five new chemical entities specifically
developed against TB. However, this slender pipeline is
not likely to be sufficient. New drugs are needed that
have strong, synergistic and complementary activities
against various M. tuberculosis subpopulations in order
to shorten TB treatment, be effective against MDRTB/XDR-TB, and be easily administered in conjunction
with ART. Furthermore, from a programmatic standpoint, it is imperative to test new combinations of new
and old drugs in order to avoid misuse of the new
compounds and prevent emergence of novel resistance.
This calls for the development of a broader drug pipeline
and a new paradigm for the identification of novel TB
drug combinations. It requires the wide involvement of
all relevant parties (industry, academia, drug regulatory
agencies, and international policy-making agencies) who
must collaborate effectively to deliver optimal future
therapies for TB.
Acknowledgements
The authors wish to thank Dr Zhenkun Ma and Dr Omar Vandal for their
help in collecting information on new drugs for TB.
A.V. works with a TB clinical trials group that sometimes collaborates
with pharmaceutical manufacturers. He reports no financial conflicts.
References and recommended reading
Papers of particular interest, published within the annual period of review, have
been highlighted as:
of special interest
of outstanding interest
Additional references related to this topic can also be found in the Current
World Literature section in this issue (pp. 287–288).
1
Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis
undertaken by the British Medical Research Council Tuberculosis Units,
1946–1986. Int J Tuberc Lung Dis 1999; 3:S231–S279.
2
Cox HS, Morrow M, Deutschmann PW. Long term efficacy of DOTS regimens
for tuberculosis: systematic review. BMJ 2008; 336:484–487.
3
Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from
first-line antituberculosis drugs among patients treated for active tuberculosis.
Am J Respir Crit Care Med 2003; 167:1472–1477.
4
Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for
treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364:1244–1251.
Conclusion
Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of
rifampin on tuberculosis treatment outcomes: a systematic review and metaanalysis. PLoS Med 2009; 6:e1000146.
This is the first ever done systematic review and meta-analysis of treatment
regimens for active TB, investigating the effect of duration and intermittency of
rifampin use on TB treatment outcomes. This analysis found that TB treatment
outcomes were significantly worse with shorter duration of rifampin, or with initial
drug resistance to isoniazid, streptomycin, or both. Treatment outcomes were
similar with all intermittent schedules evaluated, but there was insufficient evidence
to support administration of treatment twice weekly throughout therapy.
TB continues to be one of the greatest challenges in
global health. Current therapeutic agents against TB are
life-saving for many patients, but cannot overcome
increasing new challenges, including the creation and
dissemination of MDR-TB/XDR-TB and the need for
simultaneous treatment of TB and HIV. Recent advances
in TB drug research and development are encouraging,
6 WHO. Treatment of tuberculosis: guidelines, 4th ed. [WHO/HTM/TB/
2009.420]. Geneva, Switzerland: World Health Organization; 2009.
The new WHO treatment guidelines have some important changes compared with
former ones. Most important is that the 8-month ethambutol-containing regimen
has been abandoned in view of the higher rates of failures and relapses seen in
meta-analyses. Other changes include more restricted recommendations for the
use of intermittent regimens, use of ‘retreatment’ regimen and indications for
appropriate use of MDR-TB treatment, and daily intensive phase for joint treatment
of TB and HIV. All previously treated patients should have culture and DST prior to
start of treatment.
5
192 Infectious diseases
7
World Health Organization. Treatment of tuberculosis: guidelines for national
programmes WHO/CDS/TB/2008 (revised); June 2008. 108 p.
8
Mak A, Thomas A, Granado M, et al. Influence of multidrug resistance on
tuberculosis treatment outcomes with standardized regimens. Am J Respir
Crit Care Med 2008; 178:306–312.
9
Espinal M, Raviglione MC. From threat to reality: the real face of multidrugresistant tuberculosis. Am J Respir Crit Care Med 2008; 178:216–217.
10 Kimerling ME, Kluge H, Vezhnina N, et al. Inadequacy of the current WHO retreatment regimen in a central Siberian prison: treatment failure and MDR-TB.
Int J Tuberc Lung Dis 1999; 3:451–453.
11 Becerra MC, Freeman J, Bayona J, et al. Using treatment failure under effective
directly observed short-course chemotherapy programs to identify patients
with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000; 4:108–
114.
12 Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active
tuberculosis in patients with previous treatment and/or with mono-resistance
to isoniazid: a systematic review and meta-analysis. PLoS Med 2009;
6:e1000150.
This is the first report investigating evidence on the use of the WHO recommended
‘retreatment’ regimen for patients with a history of previous treatment or documented isoniazid monoresistance. This review found that there were few published
studies to support the use of the current standardized retreatment regimen. A
pooled analysis of 33 trials in 1907 patients with monoresistance to isoniazid
showed that a longer duration of rifampin, use of streptomycin, daily therapy
initially, and treatment with a higher number of effective drugs was associated with
lower failure, relapse, and acquired drug resistance rates.
23 Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune
reconstitution inflammatory syndrome: case definitions for use in resourcelimited settings. Lancet Infect Dis 2008; 8:516–523.
This is the report of a consensus meeting in which case definitions for paradoxical
TB-associated IRIS, ART-associated TB, and unmasking TB-associated IRIS were
developed for standard use in high-income and resource-limited settings.
24 Boulle A, Van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and
efavirenz-based antiretroviral therapy when coadministered with rifampicinbased antitubercular therapy. JAMA 2008; 300:530–539.
This cohort study suggested that efavirenz-based ART could be used in conjunction with rifampicin-based therapy in HIV patients coinfected with TB with similar
efficacy as in HIV patients with no TB, whereas virological outcomes were inferior
when nevirapine-based ART was commenced while taking antitubercular treatment.
25 Manosuthi W, Sungkanuparph S, Tantanathip P, et al. A randomized trial
comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients
receiving rifampicin: the N2R Study. Clin Infect Dis 2009; 48:1752–1759.
26 L’homme RF, Nijland HM, Gras L, et al. Clinical experience with the combined
use of lopinavir/ritonavir and rifampicin. AIDS 2009; 27:863–865.
27 Boulanger C, Hollender E, Farrell K, et al. Pharmacokinetic evaluation of
rifabutin in combination with lopinavir–ritonavir in patients with HIV infection
and active tuberculosis. Clin Infect Dis 2009; 49:1305–1311.
28 Khachi H, O’Connell R, Ladenheim D, Orkin C. Pharmacokinetic interactions
between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. J Antimicrob Chemother 2009; 64:871–873.
13 World Health Organization. Stop TB Dept. Guidelines for the programmatic
management of drug-resistant tuberculosis. Emergency Update 2008 [WHO/
HTM/TB/2008.402]. Geneva, Switzerland: World Health Organization;
2008.
These new guidelines present some important innovations in the management of
MDR-TB and XDR-TB, especially in patients with dual HIV–TB infection. The
guidelines, first, stress the use of rapid DST in all HIV-infected patients who are
smear-positive and quick enrolment on treatment in order to avoid the high
mortality associated with untreated MDR-TB; second, it introduces the use of
DST for second-line drugs for XDR-TB case finding; third, it strongly recommends
to introduce outpatient models of care, preferably community-based, with a
patient-centered approach; and fourth, it emphasizes infection control, especially
in congregate settings, with detailed guidance.
29 Comstock GW, Baum C, Snider DE Jr. Isoniazid prophylaxis among Alaskan
Eskimos: a final report of the Bethel isoniazid studies. Am Rev Respir Dis
1979; 119:827–830.
14 Kliiman K, Altraja A. Predictors of poor treatment outcome in multi and
extensively drug-resistant pulmonary TB. Eur Respir J 2009; 33:1085–1094.
33 Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month
regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus
rifampin for treatment of latent tuberculosis infection in children: results of an
11-year randomized study. Clin Infect Dis 2007; 45:715–722.
15 Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients
with multidrug-resistant tuberculosis: systematic review and meta-analysis.
Lancet Infect Dis 2009; 9:153–161.
This is the first systematic review of treatment outcomes among patients with
MDR-TB that analysed the effect of differences in treatment regimen design, study
methodology, and patient population. This study showed that successful outcome
was related to treatment duration (at least 18 months) and use of directly observed
therapy (DOT) throughout treatment.
16 Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes
of multidrug-resistant tuberculosis: a systematic review and meta-analysis.
PLoS One 2009; 4:e6914.
This is the second systematic review and meta-analysis of treatment outcome in
MDR-TB patients published in 2009. Results were about the same as the above
review. In addition, authors identified several factors associated with poor outcomes (male sex, alcohol abuse, low BMI, smear positivity at diagnosis, fluoroquinolone resistance, and presence of an XDR resistance pattern). Factors
associated with successful outcome were surgical intervention, absence of previous treatment, and fluoroquinolone use.
30 International Union Against Tuberculosis Committee on Prophylaxis. Efficacy
of various durations of isoniazid preventive therapy for tuberculosis: five years
of follow-up in the IUAT trial. Bull World Health Organ 1982; 60:555–564.
31 Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing
tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev
2000:CD001363.
32 Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared
with standard therapy with isoniazid, for latent tuberculosis infection: a metaanalysis. Clin Infect Dis 2005; 40:670–676.
34 Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin
therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a
randomized trial. Ann Intern Med 2008; 149:689–697.
35 Ziakas PD, Mylonakis E. 4 months of rifampin compared with 9 months of
isoniazid for the management of latent tuberculosis infection: a meta-analysis
and cost-effectiveness study that focuses on compliance and liver toxicity.
Clin Infect Dis 2009; 49:1883–1889.
This meta-analysis of the published studies on compliance, toxicity, and cost
effectiveness of the two strategies suggests that the 4-month rifampin therapy is
associated with improved compliance, safety, and cost compared with 9-month
isoniazid.
36 Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV
infected persons. Cochrane Database Syst Rev 2006:CD000171.
17 O’Donnell MR, Padayatchi N, Master I, et al. Improved early results for patients
with extensively drug-resistant tuberculosis and HIV in South Africa. Int J
Tuberc Lung Dis 2009; 13:855–861.
37 Landry J, Menzies D. Preventive chemotherapy. Where has it got us? Where
to go next? Int J Tuberc Lung Dis 2008; 12:1352–1364.
This study gives a good review and update of the tools for identification of persons
with LTBI and of the potential preventive treatment regimens to be used in various
populations the most at risk of developing disease.
18 World Health Organization. Prevention and control of multidrug-resistant
tuberculosis and extensively drug-resistant tuberculosis [WHA62.15].
62nd World Health Assembly; 22 May 2009.
38 Diacon AH, Patientia RF, Venter A, et al. Early bactericidal activity of high-dose
rifampin in patients with pulmonary tuberculosis evidenced by positive sputum
smears. Antimicrob Agents Chemother 2007; 51:2994–2996.
19 Lawn SD, Gail-Bekker L, Miller R. Immune reconstitution disease associated
with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361–373.
20 Blanc FX, Havlir DV, Onyebujoh PC, et al. Treatment strategies for HIVinfected patients with tuberculosis: ongoing and planned clinical trials. J Infect
Dis 2007; 196 (Suppl 1):S46–S51.
39 Keung AC, Owens RC Jr, Eller MG, et al. Pharmacokinetics of rifapentine in
subjects seropositive for the human immunodeficiency virus: a phase I study.
Antimicrob Agents Chemother 1999; 43:1230–1233.
40 Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in
patients with HIV-related tuberculosis treated with once-weekly rifapentine
and isoniazid. Lancet 1999; 353:1843–1847.
21 World Health Organization. Rapid advice: antiretroviral therapy for HIV
infection in adults and adolescents. Geneva, Switzerland: WHO; November
2009.
41 Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a
week versus rifampicin and isoniazid twice a week for treatment of drugsusceptible pulmonary tuberculosis in HIV-negative patients: a randomised
clinical trial. Lancet 2002; 360:528–534.
22 Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIVinfected persons in the era of highly active antiretroviral therapy. AIDS 2002;
16:75–83.
42 Rosenthal IM, Williams K, Tyagi S, et al. Potent twice-weekly rifapentinecontaining regimens in murine tuberculosis. Am J Respir Crit Care Med 2008;
178:989–993.
New drugs–regimens for the treatment of TB Lienhardt et al.
193
43 Rosenthal IM, Zhang M, Williams KN, et al. Daily dosing of rifapentine cures
tuberculosis in three months or less in the murine model. PLoS Med 2007;
4:e344.
58 Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000;
405:962–966.
44 Gillespie SH, Kennedy N. Fluoroquinolones: a new treatment for tuberculosis? Int J Tuberc Lung Dis 1998; 2:265–271.
59 Singh R, Manjunatha U, Boshoff HI, et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008; 322:
1392–1395.
45 Moadebi S, Harder CK, Fitzgerald MJ, et al. Fluoroquinolones for the treatment
of pulmonary tuberculosis. Drugs 2007; 67:2077–2099.
46 Rodriguez JC, Ruiz M, Climent A, Royo G. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 2001;
17:229–231.
47 Rodriguez JC, Ruiz M, Lopez M, Royo G. In vitro activity of moxifloxacin,
levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int
J Antimicrob Agents 2002; 20:464–467.
48 Hu Y, Coates AR, Mitchison DA. Sterilizing activities of fluoroquinolones
against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47:653–657.
49 Sulochana S, Rahman F, Paramasivan CN. In vitro activity of fluoroquinolones
against Mycobacterium tuberculosis. J Chemother 2005; 17:169–173.
50 Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilizing
activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.
Int J Tuberc Lung Dis 2008; 12:128–138.
This phase IIb trial measured the rate of decline of viable colony counts in the
intensive phase of treatment, using various combinations of drugs including
fluoroquinolones (ofloxacin, gatifloxacin, and moxifloxacin) substituted for ethambutol in the standard WHO recommended 6-month regimen. This study applied
new modelling techniques for best estimation of fall in counts in unit time for each
patient with each regimen, thus allowing reliable comparison of sterilizing activities
of each of the tested regimens. It also measured the activity of each regimen on
sputum culture conversion at 2 months, as well as on time to sputum culture
conversion.
51 Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the
initial treatment of tuberculosis: a double-blind, randomised, controlled phase
II trial. Lancet 2009; 373:1183–1189.
This study investigated the effect of substituting moxifloxacin for ethambutol in the
first 2 months of treatment of sputum smear-positive pulmonary TB and found a
superior activity of the moxifloxacin-containing regimen in terms of speed of sputum
culture conversion.
52 Burman WJ, Goldberg S, Johnson JL, et al. Moxifloxacin versus ethambutol in
the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit
Care Med 2006; 174:331–338.
53 Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for
isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J
Respir Crit Care Med 2009; 180:273–280.
These two studies [52,53] investigated the effect of substituting moxifloxacin for
ethambutol or isoniazid in the first 2 months of treatment of sputum smear-positive
pulmonary TB. Neither found a superior activity of the moxifloxacin-containing
regimen in terms of speed of sputum culture conversion. In contrast to the Durban
[50] and Rio [51] studies, these two trials were multicenter trials and did not
standardize laboratory methods.
54 Ginsberg AM, Spigelman M. Challenges in tuberculosis drug research and
development. Nat Med 2007; 13:290–294.
55 Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on
the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307:223–
227.
56 Rustomjee R, Diacon AH, Allen J, et al. Early bactericidal activity and
pharmacokinetics of the diarylquinoline TMC-207 in treatment of pulmonary
tuberculosis. Antimicrob Agents Chemother 2008; 52:2831–2835.
57 Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for
multidrug-resistant tuberculosis. N Engl J Med 2009; 360:2397–2405.
This is the first report of a phase II trial carried out with a new chemical entity
purposely developed to treat TB. This trial used the original design of testing for
microbiological efficacy when added to an optimized background therapy in
patients with MDR-TB [see also Barry CE 3rd. Unorthodox approach to the
development of a new antituberculosis therapy. N Engl J Med 2009; 360:
2466–2467].
60 Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro
and in mice. PLoS Med 2006; 3:e466
61 Ginsberg AM, Laurenzi MW, Rouse DJ, et al. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob Agents Chemother
2009; 53:3720–3725.
62 Diekema DJ, Jones RN. Oxazolidinone antibiotics. Lancet 2001; 358:1975–
1982.
63 Dietze R, Hadad DJ, McGee B, et al. Early and extended early bactericidal
activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med
2008; 178:1180–1185.
64 Migliori GB, Eker B, Richardson MD, et al. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34:387–393.
65 Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrugresistant tuberculosis. Clin Infect Dis 2010; 50:49–55.
66 Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the
treatment of intractable multidrug-resistant and extensively drug-resistant
tuberculosis. J Antimicrob Chemother 2009; 64:388–391.
67 Cynamon MH, Klemens SP, Sharpe CA, Chase S. Activities of several novel
oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999; 43:1189–1191.
68 Williams KN, Stover CK, Zhu T, et al. Promising antituberculosis activity of the
oxazolidinone PNU-100480 relative to that of linezolid in a murine model.
Antimicrob Agents Chemother 2009; 53:1314–1319.
69 Williams KN, Brickner SJ, Stover CK, et al. Addition of PNU-100480 to firstline drugs shortens the time needed to cure murine tuberculosis. Am J Respir
Crit Care Med 2009; 180:371–376.
70 Lee RE, Protopopova M, Crooks E, et al. Combinatorial lead optimization of
[1,2]-diamines based on ethambutol as potential antituberculosis preclinical
candidates. J Comb Chem 2003; 5:172–187.
71 Nikonenko BV, Protopopova M, Samala R, et al. Drug therapy of experimental
tuberculosis (TB): improved outcome by combining SQ109, a new diamine
antibiotic, with existing TB drugs. Antimicrob Agents Chemother 2007; 51:
1563–1565.
72 Showalter HD, Denny WA. A roadmap for drug discovery and its translation to
small molecule agents in clinical development for tuberculosis treatment.
Tuberculosis (Edinb) 2008; 88 (Suppl 1):S3–S17.
This remarkable review describes the key stages of drug discovery and early
development, including target identification and validation, assay development and
screening, confirmed hits to leads, lead optimization, and progressing development candidates to an investigational new drug filing, and provides particular
examples of this process in the development of small-molecule treatments for TB.
73 Nunn AJ, Phillips PP, Gillespie SH. Design issues in pivotal drug trials for drug
sensitive tuberculosis (TB). Tuberculosis (Edinb) 2008; 88 (Suppl 1):S85–
S92.
With the increasing number of new products being advanced through preclinical
and clinical development, the whole issue of clinical trial design to evaluate safety
and efficacy has to be reevaluated. This review describes very clearly the points to
be addressed when developing phase III trials for drug-susceptible TB with new
drugs, regimens, or both.
74 Sacks LV, Behrman RE. Developing new drugs for the treatment of drug
resistant tuberculosis: a regulatory perspective. Tuberculosis (Edinb) 2008;
88 (Suppl 1):S93–S100.
Simplifying and shortening treatment for drug-sensitive TB and providing new
treatment options for drug-resistant TB constitute two principal goals in the
development of novel drugs for TB. This study describes a new approach of
investigating efficacy of novel treatments in the setting of drug-resistant disease.